An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.
EP. 1: Myeloproliferative Neoplasms: Essential Thrombocythemia
Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.
EP. 2: Managing Patients with Essential Thrombocythemia
Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
EP. 3: Myeloproliferative Neoplasms: Polycythemia Vera
Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
EP. 4: Treatment Options for Polycythemia Vera
An overview of the treatment options for patients with polycythemia vera.
EP. 5: PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
EP. 6: Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
EP. 7: Myeloproliferative Neoplasms: Myelofibrosis
Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
EP. 8: Risk Stratification for Myelofibrosis
The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
EP. 9: Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials
A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.
EP. 10: New JAK Inhibitors in Myelofibrosis Treatment
Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.
EP. 11: Efficacy and Safety of JAK Inhibitors for Myelofibrosis
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
EP. 12: Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
EP. 13: Novel Agents Under Investigation for Myelofibrosis
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
EP. 14: Management of Accelerated Phase Myeloproliferative Neoplasms
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
EP. 15: Clinical Scenario: A 67-Year-Old with Myelofibrosis
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
EP. 16: Myelofibrosis Treatment Approaches after Disease Progression
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
EP. 17: Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
EP. 18: The Future of Myeloproliferative Neoplasm Treatment
The panelists conclude their discussion by highlighting investigational agents to look forward to.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer